In the Era of Generic Cardiovascular Agents, Can Emerging Therapies Achieve Substantial Clinical Differentiation to Gain Widespread Use? Chronic heart failure (CHF) describes the long-term…
The lackluster global antibiotics pipeline and surge of antibiotic resistance in clinical isolates in China have triggered a new quest for novel antibiotics against complicated HTI. Many local and…
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…
In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…
In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…
Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis? Despite contributing a…
Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis? Despite contributing a…
What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…
What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
How Receptive Are Retinal Specialists and Payers to Emerging Therapies Offering Vision Improvements or Greater Dosing Convenience? Anti-vascular endothelial growth factor (VEGF) therapies…
How Receptive Are Retinal Specialists and Payers to Emerging Therapies Offering Vision Improvements or Greater Dosing Convenience? Anti-vascular endothelial growth factor (VEGF) therapies…
Oncology prescribing has changed with the broad adoption of clinical pathways programs, bundled payment arrangements, and accountable care organizations (ACOs). Each of these managed care reforms…
Last Updated 13 December 2013 The prostate cancer market has witnessed considerable changes over the last three years, owing to the launch of five new therapies for treatment of metastatic castrate…